Innocure Therapeutics Inc. has divulged piperidinediones as proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase cereblon (CRBN)-binding moiety covalently linked to bromodomain-containing protein 4 (BRD4)- and/or tyrosine-protein phosphatase non-receptor type 11 (PTPN11)-targeting moiety via linker reported to be useful for the treatment of cancer.

Halda Therapeutics Opco Inc. has patented proteolysis-targeting chimeric (PROTAC) compounds comprising an E3 ubiquitin ligase cereblon (CRBN)-binding moiety covalently bonded to a protein-targeting moiety via linker reported to be useful for the treatment of cancer and hepatitis.

Gilead Sciences Inc. has presented tetracyclic compounds reported to be useful for the treatment of Zika virus infection.

Roche has synthesized pyruvate dehydrogenase kinase 1 (PDK1) inhibitors reported to be useful for the treatment of systemic lupus erythematosus, psoriasis, inflammatory bowel diseases, idiopathic pulmonary fibrosis, chronic obstructive pulmonary disease and cancer.

Blossomhill Therapeutics Inc. has identified macrocyclic compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.

Nucmito Pharmaceuticals Co. Ltd. has disclosed indene derivatives reported to be useful for the treatment of cancer and fibrosis.

Sun Yat-Sen University has divulged pyrimidodiazepanone compounds reported to be useful for the treatment of depression.

Jiangsu Chia Tai Tianqing Pharmaceutical Group Co. Ltd. has presented solute carrier family 22 member 12 (SLC22A12) inhibitors reported to be useful for the treatment of gout and hyperuricemia.

Drugs for Neglected Diseases Initiative has described pyrrolopirimidine derivatives reported to be useful for the treatment of leishmaniasis.

Chengdu Baiyu Pharmaceutical Co. Ltd. has identified piperazine derivatives acting as protein mono-ADP-ribosyltransferase TIPARP inhibitors reported to be useful for the treatment of cancer.